• Reduction of migraine attack frequency during each 28-day interval of the active treatment period as compared to each 28-day interval of the placebo treatment period, per subject. Individual migraine attacks are separated by 48-hours pain free time. A
• Reduction in days using an acute headache treatment during the active treatment period as compared to the placebo treatment period, per subject.

• •Reduction of migraine attack frequency during each 28-day interval of the active treatment period as compared to each 28-day interval of the placebo treatment period, per subject. Individual migraine attacks are separated by 48-hours pain free time. A
• •Reduction in days using an acute headache treatment during the active treatment period as compared to the placebo treatment period, per subject.

Olanzapine (o-lan-zah-peen) is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with schizophrenia and/ or bipolar disorder. The trade name for this drug is Zyprexa®. Olanzapine has not been approved by the FDA for the prevention of migraine and is experimental for the purposes of this research study.

The Jefferson Headache Center at Thomas Jefferson University has developed this clinical study to evaluate the safety and effectiveness of Olanzapine in preventing migraine headaches.

Inclusion Criteria:

• Subjects who are male or female between the ages of 18 and 65, inclusive
• Subjects who have a history of migraine with or without aura as defined by IHS criteria, for at least one year prior to screening
• Subjects who experience between 3 and 10 migraine attacks per month, for the three months preceding screening
• Subjects who have no more than 15 headache days per month
• Subjects who have been on a stable dose (no clinically significant changes) of all daily medications, for any indication, from 28 days prior to screening through the duration of the trial.
• Women who are using, or agree to use for the duration of the study, a medically acceptable form of contraception (as determined by the investigator), if female of childbearing potential.
• Subjects who are able to understand and comply with all study requirements
• Subjects who provide written informed consent prior to any study procedures being performed.

Exclusion Criteria:

• Women who are pregnant or lactating
• Subjects with an abnormal ECG that, in the investigators opinion, would expose them to increased risk of adverse events or interfere with study drug and/or analysis of efficacy/tolerability (subjects with QTC interval greater than 450ms will be excluded)
• Subjects currently taking, or have taken within the thirty days prior to screening, any neuroleptics > 1 day per week (such as Geodon, Zyprexa, Compazine, Phenergan, Seroquel and other drugs in the same class)
• Subjects currently taking or have taken within 4-weeks prior to screening any medication for the prevention of migraine
• Subjects who have failed more than two adequate trials of migraine prophylaxis, as determined by investigator
• Subjects who experience significant orthostatic hypotension, as determined by the investigator
• Subjects who, in the investigators opinion, have a history or have evidence of a medical condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability during this trial
• Subjects who, in the investigators opinion, have a history or have evidence of a psychiatric condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability during this trial.
• Subjects who have participated in an investigational drug trial in the 30 days prior to the screening visit